Hepatitis C Virus Protein Microarrays

丙型肝炎病毒蛋白微阵列

• 批准号: 6739486
• 负责人: NAUSHAD ALI
• 金额: $ 10.2万
• 依托单位: AVIDITY, LLC
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-05 至 2005-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6739486
• 关键词: binding proteins; biotechnology; biotin; cell free system; covalent bond; gene expression; genetic polymorphism; genetic strain; hepatitis C; hepatitis C virus; high throughput technology; host organism interaction; immobilized enzymes; immunologic assay /test; intermolecular interaction; microarray technology; protein purification; protein quantitation /detection; proteomics; recombinant proteins; robotics; technology /technique development; virus protein

DESCRIPTION (provided by investigator): Hepatitis C virus (HCV) is the leading cause of chronic liver diseases such as cirrhosis and hepatocellular carcinoma, and liver transplantation worldwide. The co-infection of HCV with other viruses (e.g. HIV) is becoming greater concern due to difficulties in the treatment of infected patients. At present, HCV-specific drugs or vaccines are not available. The general antiviral drugs have shown limited success and there is an urgent need for anti-HCV drugs and vaccines. Using a simple, inexpensive and efficient protein immobilization technology, we have proposed to develop prototype HCV protein microarrays during the Phase I studies. To develop the viral microarray, we have planned to utilize our unique AviTag-BirA biotinylation system for immobilization of the HCV proteomes representing different genotypes on the solid supports. The feasibility of printing HCV microarrays will lead to the commercialization of a variety of protein microarrays that will contain proteomes of several viral and bacterial agents. These microarrays have potential use in high throughput screening of drugs, and determination of infections and co-infections. The microarrays can also be used to study efficacy of putative vaccines and viral pathogenesis.

描述（由研究者提供）：乙型肝炎病毒（HCV）是慢性肝病（例如肝硬化和肝细胞癌）以及全球肝移植的主要原因。由于受感染患者的治疗困难，HCV与其他病毒（例如HIV）的共同感染变得越来越关注。目前，HCV特异性药物或疫苗不可用。一般的抗病毒药物的成功有限，迫切需要抗HCV药物和疫苗。使用简单，廉价和高效的蛋白质固定技术，我们提出了在I期研究中开发原型HCV蛋白微阵列的原型。为了开发病毒微阵列，我们计划利用我们独特的Avitag-Bira生物素化系统固定在固体支持上代表不同基因型的HCV蛋白质组。打印HCV微阵列的可行性将导致各种蛋白质微阵列的商业化，这些蛋白微阵列将包含几种病毒和细菌剂的蛋白质组。这些微阵列在药物的高通量筛查中有可能使用，并确定感染和共同感染。微阵列还可以用于研究推定疫苗和病毒发病机理的功效。